Daiichi Sankyo Entered into a Development and Commercialization Agreement with Merck for Three Daiichi Sankyo DXd ADCs
Shots:
- Daiichi Sankyo will receive $4B up front ($1.5B for ifinatamab deruxtecan due upon execution; $1.5B for patritumab deruxtecan (HER3-DXd) where $750M is due upon execution and $750M is due after 12mos.; $1B {$500M each for patritumab deruxtecan & ifinatamab deruxtecan (I-DXd)} in addition to $1.5B in continuation payments over the next 24mos. for raludotatug deruxtecan (R-DXd).
- Daiichi Sankyo is eligible for ~$16.5B incl. $5.5B for each product upon achievement of sales milestones, a total potential consideration of ~$22B. Both companies will develop & commercialize 3 DXd ADC candidates: HER3-DXd, I-DXd & R-DXd globally ex. Japan
- Daiichi Sankyo will maintain exclusive rights & will lead the manufacturing & supply. All 3 DXd ADCs are in various stages of clinical development for multiple solid tumors as monotx. & incombination with other treatments
Ref: Merck | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo and AstraZeneca Report P-III Trial (TROPION-Breast01) Results of Datopotamab Deruxtecan for Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
